Japan Biosimilars Market Size & Outlook, 2025-2033

The biosimilars market in Japan is expected to reach a projected revenue of US$ 6,553.7 thousand by 2033. A compound annual growth rate of 18.2% is expected of Japan biosimilars market from 2025 to 2033.
Revenue, 2024 (US$K)
$1,470.8
Forecast, 2033 (US$K)
$6,553.7
CAGR, 2025 - 2033
18.2%
Report Coverage
Japan

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Japan biosimilars market, 2021-2033 (US$K)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Japan biosimilars market highlights

  • The Japan biosimilars market generated a revenue of USD 1,470.8 thousand in 2024 and is expected to reach USD 6,553.7 thousand by 2033.
  • The Japan market is expected to grow at a CAGR of 18.2% from 2025 to 2033.
  • In terms of segment, monoclonal antibodies (mabs) was the largest revenue generating drug class in 2024.
  • Insulin & Analogues is the most lucrative drug class segment registering the fastest growth during the forecast period.


Biosimilars market data book summary

Market revenue in 2024USD 1,470.8 thousand
Market revenue in 2033USD 6,553.7 thousand
Growth rate18.2% (CAGR from 2025 to 2033)
Largest segmentMonoclonal antibodies (mabs)
Fastest growing segmentInsulin & Analogues
Historical data2021 - 2023
Base year2024
Forecast period2025 - 2033
Quantitative unitsRevenue in USD thousand
Market segmentationMonoclonal Antibodies (mAbs), Growth Factors & Hematopoietic Agents, Insulin & Analogues, Osteoporosis / Bone Metabolism Agents, Others Drug Class
Key market players worldwideAmgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc


Other key industry trends

  • In terms of revenue, Japan accounted for 4.3% of the global biosimilars market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Asia Pacific, China biosimilars market is projected to lead the regional market in terms of revenue in 2033.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 5,947.2 thousand by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Biosimilars Market Companies

Name Profile # Employees HQ Website
Sandoz Group AG ADR View profile - - -
Biocon View profile 10001+ Bangalore, Karnataka, India, Asia http://www.biocon.com
Samsung Bioepis View profile 501-1000 Incheon, Inch'on-jikhalsi, South Korea, Asia https://www.samsungbioepis.com
Celltrion Healthcare View profile 51-100 Incheon, Inch'on-jikhalsi, South Korea, Asia http://www.celltrionhealthcare.com/
Viatris Inc View profile 38000 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 https://www.viatris.com
Roche View profile 10001+ Basel, Basel-Stadt, Switzerland, Europe http://www.roche.com
Dr. Reddy’s Laboratories View profile 10001+ Hyderabad, Andhra Pradesh, India, Asia http://www.drreddys.com/
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com
AbbVie Inc View profile 50000 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 http://www.abbvieinvestor.com
Amgen Inc View profile 26700 One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 https://www.amgen.com
Teva Pharmaceutical Industries Ltd View profile 37851 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 https://www.tevapharm.com

Japan biosimilars market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilars market will help companies and investors design strategic landscapes.


Monoclonal antibodies (mabs) was the largest segment with a revenue share of 52.45% in 2024. Horizon Databook has segmented the Japan biosimilars market based on monoclonal antibodies (mabs), growth factors & hematopoietic agents, insulin & analogues, osteoporosis / bone metabolism agents, others drug class covering the revenue growth of each sub-segment from 2021 to 2033.


Reasons to subscribe to Japan biosimilars market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan biosimilars market databook

  • Our clientele includes a mix of biosimilars market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan biosimilars market , including forecasts for subscribers. This country databook contains high-level insights into Japan biosimilars market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan biosimilars market size, by drug class, 2021-2033 (US$K)

Japan Biosimilars Market Outlook Share, 2024 & 2033 (US$K)

Japan biosimilars market size, by drug class, 2021-2033 (US$K)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online